Literature DB >> 8967352

Evidence for presence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocyte.

R C Gupta1, J Neumann, A M Watanabe, M Lesch, H N Sabbah.   

Abstract

Protein phosphatase inhibitor-1 (PPI-1) has been shown to be present in heart tissue and smooth muscle. Whether PPI-1 is present in cardiomyocytes is not known. The purpose of this study was to determine whether PPI-1 is present and is hormonally regulated in cardiomyocytes. A trichloroacetic acid (TCA) extract enriched in PPI-1 was isolated from guinea pig ventricular cardiomyocytes. The TCA extract inhibited the activity of type 1 protein phosphatase by 20 +/- 4% (n = 3 expts). On phosphorylation by the catalytic subunit of adenosine 3', 5'-cyclic monophosphate-dependent protein kinase, the extent of this inhibition was augmented to 4.5-fold. Dephosphorylation of the phosphorylated TCA extract by type 2 protein phosphatase reduced inhibition to 2 +/- 0.2% (n = 3 expts). To determine whether isoproterenol increases phosphorylation of PPI-1 in cardiomyocytes, the TCA extracts were prepared from cardiomyocytes treated with 1 microM isoproterenol and from untreated cardiomyocytes. The inhibitory activity of the TCA extract in untreated cardiomyocytes was 25 +/- 3% (n = 3 expts) and increased to 75 +/- 2% (n = 3 expts) in isoproterenol-treated cardiomyocytes. With the use of a rabbit skeletal muscle PPI-1 antibody, immunoblots of the TCA extract of cardiomyocytes identified a 28-kDa protein. A 28-kDa protein was also immunoprecipitated from a TCA extract isolated from isoproterenol-treated 32P-labeled cardiomyocytes. The immunoprecipitation was blocked by the addition of excess amounts of purified rabbit skeletal muscle PPI-1. Isoproterenol-treated cardiomyocytes increased the phosphorylation of the 28-kDa protein by 232 +/- 20% (n = 3 expts) compared with untreated cardiomyocytes. We conclude that 1) the 28-kDa protein is PPI-1, 2) PPI-1 is present in ventricular cardiomyocytes, and 3) PPI-1 is hormonally regulated. A decrease in type 1 protein phosphatase activity through phosphorylation of PPI-1 may be an important pathway for augmenting cardiac contractility.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8967352     DOI: 10.1152/ajpheart.1996.270.4.H1159

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  20 in total

1.  Type 1 phosphatase, a negative regulator of cardiac function.

Authors:  Andrew N Carr; Albrecht G Schmidt; Yoichi Suzuki; Federica del Monte; Yoji Sato; Carita Lanner; Kristine Breeden; Shao-Ling Jing; Patrick B Allen; Paul Greengard; Atsuko Yatani; Brian D Hoit; Ingrid L Grupp; Roger J Hajjar; Anna A DePaoli-Roach; Evangelia G Kranias
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

2.  Constitutive phosphorylation of inhibitor-1 at Ser67 and Thr75 depresses calcium cycling in cardiomyocytes and leads to remodeling upon aging.

Authors:  Stela Florea; Ahmad Anjak; Wen-Feng Cai; Jiang Qian; Elizabeth Vafiadaki; Sarah Figueria; Kobra Haghighi; Jack Rubinstein; John Lorenz; Evangelia G Kranias
Journal:  Basic Res Cardiol       Date:  2012-07-10       Impact factor: 17.165

3.  Contractile responses to selective phosphodiesterase inhibitors following chronic beta-adrenoreceptor activation.

Authors:  Oleg E Osadchii; Angela J Woodiwiss; Gavin R Norton
Journal:  Pflugers Arch       Date:  2005-12-17       Impact factor: 3.657

4.  AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling.

Authors:  Kenneth M Fish; Dennis Ladage; Yoshiaki Kawase; Ioannis Karakikes; Dongtak Jeong; Hung Ly; Kiyotake Ishikawa; Lahouaria Hadri; Lisa Tilemann; Jochen Muller-Ehmsen; R Jude Samulski; Evangelia G Kranias; Roger J Hajjar
Journal:  Circ Heart Fail       Date:  2012-12-27       Impact factor: 8.790

5.  Regulation of protein phosphatase inhibitor-1 by cyclin-dependent kinase 5.

Authors:  Chan Nguyen; Akinori Nishi; Janice W Kansy; Joseph Fernandez; Kanehiro Hayashi; Frank Gillardon; Hugh C Hemmings; Angus C Nairn; James A Bibb
Journal:  J Biol Chem       Date:  2007-03-30       Impact factor: 5.157

6.  Reduced inhibitor 1 and 2 activity is associated with increased protein phosphatase type 1 activity in left ventricular myocardium of one-kidney, one-clip hypertensive rats.

Authors:  Ramesh C Gupta; Sudhish Mishra; Xiao-Ping Yang; Hani N Sabbah
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

Review 7.  Intracellular devastation in heart failure.

Authors:  Federica Del Monte; Roger J Hajjar
Journal:  Heart Fail Rev       Date:  2008-06       Impact factor: 4.214

8.  The human G147D-protein phosphatase 1 inhibitor-1 polymorphism is not associated with altered clinical characteristics in heart failure.

Authors:  Guoli Chen; Xiaoyang Zhou; Anand Pathak; Gerald W Dorn; Evangelia G Kranias
Journal:  Cardiology       Date:  2008-08-12       Impact factor: 1.869

9.  Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality.

Authors:  Nicole Brüchert; Nirmala Mavila; Peter Boknik; Hideo A Baba; Larissa Fabritz; Ulrich Gergs; Uwe Kirchhefer; Paulus Kirchhof; Marek Matus; Wilhelm Schmitz; Anna A DePaoli-Roach; Joachim Neumann
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-08       Impact factor: 4.733

Review 10.  Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology.

Authors:  Persoulla Nicolaou; Roger J Hajjar; Evangelia G Kranias
Journal:  J Mol Cell Cardiol       Date:  2009-05-27       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.